Abstract
Objective: This study was performde to evaluate the efficacy of paclltaxel based combination chemotherapy by response rate and survival time in the treatment of recurrent endometrial cancer. Methods:From May 1995 to February 20041 27 out of 301 cases of endometrial treated at the Asan Medical Center in Seoul were recurrent. We identifiled 11 patients treated with paclitaxel based combination chemotherapy after recurrence to the death or last visit. Results: The non- paclitaxel based combination chemotherapy group showed partial response in 1 cases (14.3%) and disease progression in 4 (57.1%). In contrast, the paclitaxel group showed 7 cases (636%) of partial response. The median survival time for total study patients was 18.0 months, 22.0 months for paclitaxel group and 15.0 months for the non-paclitaxel group, the difference being statistically significant (p=0.047). Side effect of chemotherapy such as leukopenia, neutropenia and thrombocytopenia showed no difference between the two groups. Conclusion: Paclitaxel-based combination chemotherapy may be the first-line chemotherapeutic agent in recurrent endometrial cancer patients if it's effective than other combination chemotherapy in prolonging survival times.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
